As­traZeneca's Imfinzi com­bo ex­tends PFS in liv­er can­cer; No­var­tis shares new de­tails about Lu­tather­a's PhI­II

Here are the lat­est da­ta from AS­CO’s Gas­troin­testi­nal Can­cers Sym­po­sium:

Imfinzi com­bo ex­tends pro­gres­sion-free sur­vival in liv­er can­cer: In a Phase III tri­al, As­traZeneca’s …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER